Conditions: Non-Small-Cell Lung Cancer
Keywords: Non-Small-Cell Lung Cancer NSCLC Panitumumab Vectibix Pemetrexed Alimta Carboplatin
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 70
Healthy volunteers: no

Brief summary:
The purpose of this multicenter, Phase II trial is to examine the role of a well-tolerated novel agent, panitumumab, in combination with a modern platinum doublet regimen using carboplatin and pemetrexed, in patients with advanced non-squamous wild type K-ras non-small-cell lung cancer (NSCLC). If this treatment proves to be well tolerated and associated with efficacy, this would provide rationale for further randomized studies.

Detailed description:

Arms:
arm 1: Systemic Therapy

Interventions: intervention 1: Carboplatin intervention 2: Pemetrexed intervention 3: Panitumumab
Intervention descriptions: intervention 1: Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length) intervention 2: Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length) intervention 3: Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)

Protocol document: